The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

The recent US Food and Drug Administration expanded indication for sacubitril/valsartan
introduces a new potential taxonomy for heart failure, with no reference to “preserved” …

Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …

Heart failure with preserved ejection fraction (HFpEF) represents a highly heterogeneous
clinical syndrome affected in its development and progression by many comorbidities. The …

In the last years, major progress occurred in heart failure (HF) management. Quadruple
therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst …

Background The prevalence and prognostic impact of tricuspid regurgitation (TR) remain
incompletely characterized. Methods The distribution of TR severity was analyzed in …

Current guidelines recommend that clinical surveillance for patients with moderate aortic
stenosis (AS) and aortic valve replacement (AVR) may be considered if there is an indication …

The syndrome of heart failure (HF) has historically been dichotomized based on clinical trial
inclusion criteria into patients with a reduced or preserved left ventricular ejection fraction …

Focused cardiac ultrasound (FoCUS) is becoming standard practice in a wide spectrum of
clinical settings. There is limited data evaluating the real-world use of FoCUS with artificial …

BACKGROUND: Recent guidelines proposed a classification for heart failure (HF) on the
basis of left ventricular ejection fraction (LVEF), although it remains unclear whether the …